ExpreS2ion Biotechnologies – Presentation of Q3 2023 results
HC Andersen Capital
This morning, Expres2ion Biotechnology released its Q3 2023 results. In a virtual live event today with CEO Bent Frandsen and CFO Keith Alexander we went through the results and achievements of the quarter. The management gave an update on the pipeline and lastly a status on the new strategy, focusing more on projects with shorter time to development and less risk.
ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its non-viral Drosophila S2 cells-based expression system.
Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis 14.45, 16 November 2023.
